The intestinal microbiome and the leaky gut as therapeutic targets in alcoholic liver disease

Philipp Hartmann1, Wei-Chung Chen2 and Bernd Schnabl1*

1 Department of Medicine, University of California San Diego, La Jolla, CA, USA
2 Department of Medicine, The Methodist Hospital, Weill Cornell College, Houston, TX, USA

Edited by:
Stephen J. Pandol, University of California, Los Angeles, USA
Reviewed by:
Stephen J. Pandol, University of California, Los Angeles, USA
Kouhei Fukushima, Tohoku University, Japan
*Correspondence:
Bernd Schnabl, Department of Medicine, University of California San Diego, MC0702, 9500 Gilman Drive, La Jolla, CA 92093, USA.
e-mail: beschnabl@ucsd.edu

Alcoholic liver disease (ALD) encompasses hepatic steatosis, which may progress to alcoholic hepatitis, fibrosis, and cirrhosis. It remains a leading cause of morbidity and mortality in the US and worldwide. The severity of liver disease correlates with plasma levels of bacterial products in patients, and experimental ALD depends on the level of gut-derived bacterial products in rodents. Since intestinal decontamination and deficiency of bacterial product receptors or their downstream signaling molecules protect from alcohol-induced liver disease, bacterial translocation (BT), qualitative, and quantitative changes of the enteric microbiome are considered as being of fundamental importance in the pathogenesis of ALD. Recent enhancements in diagnostic technologies provide a better insight into these shifts. This review highlights vital events in ALD such as BT, the importance of Toll-like receptor (TLR) signaling, intestinal bacterial overgrowth (IBO), and changes in the intestinal microbiome. Furthermore, a treatment trial section of patients reviews possible future options of therapy for ALD modifying the enteric microbiome.

Keywords: alcoholic liver disease, microbiome, bacterial translocation, bacterial overgrowth, bacterial dysbiosis, steatohepatitis

INTRODUCTION

Liver cirrhosis is the 12th leading cause of death in the United States, and 48% of all cirrhotic deaths are alcohol-related (Yoon and Yi, 2010). Hepatic steatosis or fatty liver is the most common hepatic phenotype of alcoholic liver disease (ALD) and is characterized by excessive fat accumulation in hepatocytes. It may progress to alcoholic hepatitis, fibrosis, and cirrhosis (Adachi and Brenner, 2005; Tilg and Day, 2007). Hepatocyte injury and infiltration of the liver by inflammatory cells including neutrophils are found in alcoholic hepatitis. Finally, alcoholic fibrosis is characterized by excessive accumulation of extracellular matrix proteins, most commonly in response to inflammation of the liver. Advanced liver fibrosis may lead to cirrhosis, liver failure, and portal hypertension. In many cases, liver transplantation is needed. Fatty liver can be reversed within a few weeks of abstinence (Lieber et al., 1965). However, it constitutes a risk factor for progression to fibrosis and cirrhosis in patients with severe steatosis that continue to consume alcohol (Sorensen et al., 1984; Teli et al., 1995). The risk of developing liver cirrhosis increases with elevated alcohol intake. An augmented risk was established in men with a daily alcohol intake above 60–80 g and in women above 20 g. Yet, only 6–41% of the subjects with excessive alcohol consumption develop cirrhosis (Mandayam et al., 2004). 46% of all patients with decompensated cirrhosis at the time of diagnosis die within 2 years (D’Amico et al., 2006). Mortality from ALD has been decreasing in recent years, likely due to improvements in clinical management of common complications including portal hypertension and bleeding esophageal varices (Paula et al., 2010). Nevertheless, a Danish study found 27- and 35-fold excessive mortality from alcoholic cirrhosis in men and women, respectively (Kamper-Jorgensen et al., 2004). The infection-attributed mortality in general of bacterial infections in cirrhotic patients has been reported to be 30–50% which could be caused by residing intestinal bacteria as in spontaneous bacterial peritonitis (SBP) or by non-intestinal bacteria as in respiratory tract infections or in tuberculosis with an overall similar fatality (Christou et al., 2007; Arvaniti et al., 2010). Infections in subjects with cirrhosis—all causes combined— increase mortality by 4-fold; 30% of patients succumb to bacterial infections within the first month and another 30% die by 1 year (Arvaniti et al., 2010).

There is strong evidence for a gut-liver axis that is causatively linked not only to progression of alcohol-induced liver disease but also to infections, both in patients and experimental animal models.

This review highlights central events in ALD such as bacterial translocation (BT), Toll-like receptor (TLR) stimulation via bacterial ligands and consequent steps, intestinal bacterial overgrowth (IBO), and dysbiosis, as well as clinical trials of various treatment modalities of patients with ALD. It additionally refers to other etiologies of liver disease and the implication of the microbiome/bacteria therein.
**BACTERIAL TRANSLOCATION**

BT is defined as migration of viable bacteria or bacterial products from the gastrointestinal tract through the epithelium to mesenteric lymph nodes or other extraintestinal organs (Berg and Garlington, 1979). BT is initiated when there is damage to the epithelium (Mathurin et al., 2000; Parlesak et al., 2000; Keshavarzian et al., 2001; Rao et al., 2004; Purohit et al., 2008).

In Caco-2 cell layers and intestinal biopsies, it has been demonstrated that acetalddehyde, an indirect oxidized metabolite of alcohol, disrupts the intestinal barrier (Rao, 1998; Basuoy et al., 2005; Purohit et al., 2008). Ethanol administration results in acute damage of the colonic epithelial barrier through acetalddehyde (metabolized by the intestinal flora) in rats and subsequently activates mast cells (Ferrier et al., 2006). In humans, ethanol intake leads to duodenal and jejunal mucosal injury (Bode and Bode, 2003). Lipopolysaccharide (LPS), a critical component of the outer membrane of Gram-negative bacteria (Fadal et al., 2005), induces macrophages to release pro-inflammatory cytokines resulting in liver injury (French, 2001). Pro-inflammatory cytokines such as IL-1β and tumor necrosis factor (TNF) have been shown to be elevated in the distal ileum of mice fed with ethanol for 2 weeks (Fleming et al., 2001). They are also known to disrupt the intestinal barrier (Wang et al., 2005; Clayburgh et al., 2006; Al-Sadi et al., 2008). This impairment has been demonstrated in duodenal biopsies of cirrhotic patients, which shows enlarged intercellular spaces below the tight junctions (Such et al., 2002). In another study, the augmented intestinal permeability existed longer than 14 days after having eschewed drinking ethanol (Bjarnason et al., 1984). In summary, these findings indicate that morphologic and functional changes may persist in the gut barrier after long-term alcohol abuse similar to lasting structural and functional alterations in the liver.

To assess the quantity of BT, bacterial products (also called pathogen-associated molecular patterns or PAMPs) or viable bacteria can be measured in the portal or systemic circulation. Plasma LPS levels were elevated in patients with alcoholic steatohepatitis and alcoholic cirrhosis (Bode et al., 1987; Fukui et al., 1991; Schafer et al., 2002). There is a direct association between ethanol administration and increased plasma LPS in animal models (Nanji et al., 1993; Adachi et al., 1995; Tamai et al., 2000). Equally in patients, endotoxemia is present in early stage of ALD prior to the onset of fibrosis or cirrhosis (Parlesak et al., 2000; Bode and Bode, 2005). The severity of liver injury positively correlates with plasma LPS levels in patients with cirrhosis (Lin et al., 1995), which could also be related to a decreased clearance of endotoxin from the blood by the liver (Satoh et al., 2008). Interestingly, plasma LPS is higher in subjects with alcoholic cirrhosis than in subjects with cirrhosis from other causes (Bode et al., 1987; Fukui et al., 1991). Peptidoglycan, the major component of Gram-positive bacterial cell walls, is higher in rat plasma following acute ethanol feeding (Tabata et al., 2002). Bacterial DNA, a surrogate marker of BT, is higher in cirrhotic rats (Guarner et al., 2006). BT even precedes IBO and intestinal dysbiosis in ALD (Yan et al., 2011) similarly to CCl4-induced liver injury (Fouts et al., 2012).

The innate immune system has conserved pattern recognition receptors, e.g., TLRs, that recognize specific PAMPs such as LPS, peptidoglycan, lipoproteins, lipoteichoic acid, double-stranded RNA, and unmethylated DNA (Akira et al., 2006). TLR2 is important in detecting Gram-positive bacteria and recognizes a number of bacterial components such as lipoproteins, peptidoglycan, and lipoteichoic acid (Aliprantis et al., 1999; Schwandner et al., 1999; Yoshimura et al., 1999). According to one study, cirrhotic patients with ascites had an increased risk of developing SBP in the presence of a specific TLR2 genotype (16934 TT genotype) or a TLR2 GT microsatellite polymorphism; presence of both risk factors further augmented the susceptibility for SBP (Nischalke et al., 2011).

The cellular receptor for endotoxin is TLR4, which plays a central role in the innate immune response to BT. After binding of LPS to its cellular receptor TLR4, MyD88-dependent and MyD88-independent (TRIF/IRF-3-dependent) pathways are activated. TLR4 mutant C3H/Hej mice and TLR4 knock-out mice had mitigated hepatic steatosis, inflammation and necrosis in ALD compared to wild type mice (Uesugi et al., 2001; Hritz et al., 2008). TLR4 signaling is important in both BM-derived cells including Kupffer cells, and endogenous liver cells including hepatic stellate cells (HSCs) for alcohol-induced hepatocyte injury, steatosis, inflammation, and fibrogenesis (Inokuchi et al., 2011). Activation of the MyD88-independent, TRIF/IRF-3-dependent pathway in the liver plays a major role in experimental ALD (Hritz et al., 2008; Petrasek et al., 2011). A comparable significance of TLR4 for liver fibrogenesis has been noted in cholestatic or toxic liver fibrosis in mice (Seki et al., 2007). Other reports indicate a similar implication of TLR4 in non-alcoholic steatohepatitis in rodents (Ye et al., 2012). The implication of TLR4 in liver disease has also been proven in human subjects: it is one of seven genes linked to an elevated risk of developing cirrhosis in patients with chronic hepatitis C (Huang et al., 2007). Specific single nucleotide polymorphisms (TLR D299G and T399I) are associated with less hepatic fibrosis (Ye et al., 2012). The activation of TLR4 in liver disease has also been proven in human subjects: it is one of seven genes linked to an elevated risk of developing cirrhosis in patients with chronic hepatitis C (Huang et al., 2007). Specific single nucleotide polymorphisms (TLR D299G and T399I) are associated with less hepatic fibrosis (Ye et al., 2012). The activation of TLR4 in liver disease has also been proven in human subjects: it is one of seven genes linked to an elevated risk of developing cirrhosis in patients with chronic hepatitis C (Huang et al., 2007). Specific single nucleotide polymorphisms (TLR D299G and T399I) are associated with less hepatic fibrosis (Ye et al., 2012).
chlordane injections largely alleviates alcohol-induced liver disease (Adachi et al., 1994; Koop et al., 1997). During hepatic inflammation, Kupffer cells produce a large variety of cytokines such as TNF-α, IL-6, IL-1, chemokines such as KC (CXCL1), MIP-2 (CXCL2), MCP-1 (CCL2), MIP-1α (CCL3), MIP-1β (CCL4), and RANTES (CCL5), and reactive oxygen species (Seki and Schnabl, 2012). In addition, they also produce pro-fibrogenic mediators, such as TGF-β and PDGF which activate quiescent HSCs to produce extracellular matrix proteins (Bataller and Brenner, 2005). Oxidative stress via alcohol and acetaldehyde sensitzes HSC to activation by LPS and consequent induction of hepatic fibrosis (Quiroz et al., 2001; Karaa et al., 2008). Similarly to Kupffer cells, HSC upon LPS stimulation express pro-inflammatory cytokines (e.g., TNF-α, IL-6) and chemokines such as CXCL1 (Schwabe et al., 2003; Seki et al., 2007). In hepatocytes, LPS can promote apoptosis, especially in conjunction with other hepatotoxic agents (Nagaki et al., 1999; Kudo et al., 2009). Thus, endotoxin affects Kupffer cells, hepatocytes, and HSC to participate in the initiation and progression of ALD.

The detailed role of the adaptive immune system for the initiation and progression of ALD remains largely unknown (Gao and Bataller, 2011).

Thus, BT not only contributes to increased infection rates and mortality in end-stage liver disease but also to disease progression in early stages of alcoholic liver injury and disease. Viable bacteria need to translocate from the intestine to extraintestinal sites to cause infections, while translocation of bacterial products is sufficient to cause disease progression in ALD.

**INTESTINAL BACTERIAL OVERGROWTH**

**OVERGROWTH OF INTESTINAL BACTERIA IN EXPERIMENTAL ALD**

The human intestine harbors 10^{13} bacteria, a quantity that outnumbers the total sum of cells in the human body of 10^{12} (Guarner and Malagelada, 2003; O’Keefe, 2008). The impressive density of 10^9 microbial cells/g contents in the jejunum mounts up to 10^{11} cells/g contents in the colon (Savage, 1977). Mice fed with alcohol via an intragastric feeding tube for 3 weeks show IBO (Yan et al., 2011). Both aerobic and anaerobic bacteria increase predominantly in the small intestine (Yan et al., 2011). IBO correlates well with increased BT. For example, experimentally induced IBO leads to BT and subsequent liver injury (Lichtman et al., 1990). On the other hand, selective intestinal deconcentration decreases BT and plasma LPS, and ameliorates the detrimental effect of LPS on the liver (Adachi et al., 1995; Enomoto et al., 1999, 2001). Bacterial overgrowth and BT are also common characteristics observed in end-stage liver disease (Parks et al., 1996; Guarner et al., 1997). Cirrhotic rats with BT have been shown with increased bacterial overgrowth (Runyon et al., 1994; Garcia-Tsao et al., 1995; Sanchez et al., 2005). Taken together, bacterial overgrowth in the intestine occurs already in an early stage of experimental ALD. In addition to alcohol, other experimental etiologies of liver disease, such as cholestasis, toxic, and non-alcoholic fatty liver disease, are accompanied by IBO (Wigg et al., 2001; Miele et al., 2009; Fouts et al., 2012).

**INTESTINAL BACTERIAL OVERGROWTH IN PATIENTS WITH ALD**

There are different diagnostic tests to detect IBO in patients. Aside from D-Xylose test where D-xylene is ingested and then measured in the urine and blood (Craig and Atkinson, 1988; Craig and Ehrenpreis, 1999), there are other breath tests used in the diagnosis of IBO. Hydrogen breath tests are based on the fact that the only source for hydrogen gas in human intestine is bacterial metabolism of carbohydrates (Levitt, 1969). For these tests, carbohydrates are ingested and the intestinal bacteria metabolize carbohydrates into hydrogen that will be detected in the breath. The most frequently used substrates for diagnosis of IBO are glucose (Metz et al., 1976; Kerlin and Wong, 1988) and lactulose (Rhodes et al., 1979; Simren and Stotzer, 2006).

Tests with labeled carbon take advantage of the bacteria’s ability to deconjugate bile acids. For example in the glycocholic acid breath test, ^{14}C glycocholic acid is administered and the ^{14}CO_2 is then measured (Donald et al., 1992). However, the gold standard to prove small-intestinal bacterial overgrowth (SIBO) is culturing of jejunal aspirates of bacteria to demonstrate at least 10^5 colony forming units/ml (Kerlin and Wong, 1988; Bauer et al., 2000; Simren and Stotzer, 2006).

Similar to findings in animal models, human subjects with SIBO exhibit an increased intestinal permeability (Riordan et al., 1997; Miele et al., 2009). It is now well-established that IBO occurs more commonly in patients with ALD. Aerobic and anaerobic bacteria are increased in jejunal aspirates from subjects with long-term alcohol use (Bode et al., 1984; Casafont Morencos et al., 1996). SIBO is more frequent in cirrhotic patients and directly correlates with the severity of liver damage (Casafont Morencos et al., 1996; Bauer et al., 2001; Pande et al., 2009; Jun et al., 2010). Equally, a higher prevalence of antibodies directed against bacterial products is noted in more advanced liver disease (Fapp et al., 2010).

Several hypotheses have been raised to explain the pathogenesis of bacterial overgrowth: impaired bile flow, intestinal dysmotility, less acidic gastric pH, and altered intestinal innate immune response.

**Impaired bile flow**

In experimental mouse models, the antimicrobials angioinogen 1 and RNAse family member 4 were found to be targets of the nuclear receptor FXR in intestinal epithelial cells, the receptor for bile acids. A decrease in these antimicrobials is associated with IBO (Inagaki et al., 2006). Oral feeding of bile acids to rats with cirrhosis has been shown to reverse bacterial overgrowth in the intestine and to lower BT and plasma LPS levels (Lorenzo-Zuniga et al., 2003). Hence, the markedly decreased bile acid secretion in cirrhotic patients into the intestine (Raedsch et al., 1983) may contribute to IBO.

**Intestinal dysmotility**

Ethanol decreases intestinal motility which may in turn cause luminal bacteria to proliferate (Bode and Bode, 2003). Patients with cirrhosis tend to have prolonged oroceleal transit time (Madrid et al., 1997; Chang et al., 1998; Gunnarsdottir et al., 2003). Similarly, SIBO with a delayed transit time was noted more commonly in cirrhotic subjects with hepatic encephalopathy.
of continuous intragastric ethanol administration showed significant differences. This is especially noteworthy as several studies have demonstrated a beneficial effect of *Lactobacillus* supplementation in experimental ALD (Nanji et al., 1994; Forsyth et al., 2009; Mutlu et al., 2009). The question arises as to whether an alcohol-associated microbiome in mice is specific for alcohol or similar changes can be also observed in other experimental liver disease models. In cholestasis, 16S rRNA sequencing could not show a significant qualitative change in the microbiome relative to control mice. In mice with CCl₄-induced toxic liver injury, dysbiosis could be observed with an elevated intestinal burden of Firmicutes and Actinobacteria (Fouts et al., 2012). In contrast to microbial changes in ALD, obesity-induced fatty liver seems to be associated with an augmented bacterial load of Firmicutes and a relative decrease in Bacteroidetes (Ley et al., 2005; Turnbaugh et al., 2009). Although experimental liver disease models depend on translocated bacterial products from the intestine, there are distinct changes in the enteric microbiome of four different experimental etiologies of liver disease.

**ENTERIC MICROBIOME**

**INTESTINAL DYSBIOSIS IN EXPERIMENTAL ALD**

The intestine provides residence to a variety of microbial communities consisting of 10 different bacterial phyla with more than 15,000 species-level bacterial phylotypes (Camp et al., 2009). The most abundant of these phylotypes in mice and humans are Firmicutes and Bacteroidetes (Eckburg et al., 2005; Ley et al., 2006; Yan et al., 2011). In a healthy state, the intestinal microflora keeps a symbiotic relationship with its host. The total bacterial burden, distribution, and composition are regulated by the host’s immune system via intestinal antimicrobial proteins. Dysbiosis is known as an imbalance between enteric microbial colonies and its associated deleterious effects on the colonized host (McLoughlin and Mills, 2011), and this has been implicated in diseases including inflammatory bowel disease (Frank et al., 2007). Only a minority of intestinal bacteria can be cultured by conventional culture techniques, but rapid advances in analytic methods have intensely enlarged our ability to study biodiversity in a microbial community (Eckburg et al., 2005; Gill et al., 2006). Offering a first glimpse into alcoholic enteric dysbiosis by using Length Heterogeneity PCR (LH-PCR) fingerprinting, one study noted a significantly changed intestinal microbiome in rats after 10 weeks of ethanol administration (Mutlu et al., 2009). It reports that probiotic or prebiotic treatment protected alcohol fed rodents from intestinal dysbiosis. Another study that performed deep DNA pyrosequencing of bacterial 16S rRNA after 3 weeks of continuous intragastric ethanol administration showed significant intestinal dysbiosis in alcohol fed mice. Dysbiosis was characterized by a profound suppression of several endogenous probiotic bacteria such as *Lactobacillus* (Yan et al., 2011). This is beneficial as several studies have demonstrated a beneficial effect of *Lactobacillus* supplementation in experimental ALD (Nanji et al., 1994; Forsyth et al., 2009; Mutlu et al., 2009). The question arises as to whether an alcohol-associated microbiome in mice is specific for alcohol or similar changes can be also observed in other experimental liver disease models. In cholestasis, 16S rRNA sequencing could not show a significant qualitative change in the microbiome relative to control mice. In mice with CCl₄-induced toxic liver injury, dysbiosis could be observed with an elevated intestinal burden of Firmicutes and Actinobacteria (Fouts et al., 2012). In contrast to microbial changes in ALD, obesity-induced fatty liver seems to be associated with an augmented bacterial load of Firmicutes and a relative decrease in Bacteroidetes (Ley et al., 2005; Turnbaugh et al., 2009). Although experimental liver disease models depend on translocated bacterial products from the intestine, there are distinct changes in the enteric microbiome of four different experimental etiologies of liver disease.

**INTESTINAL DYSBIOSIS IN PATIENTS WITH ALD**

As mentioned above, the two most abundant bacterial phyla in the intestine of humans are Firmicutes and Bacteroidetes (Eckburg et al., 2005; Ley et al., 2006). According to one study, Bacteroidetes were found to be significantly reduced and Proteobacteria and Fusobacteria highly enriched in patients with cirrhosis related to hepatitis B and alcohol abuse (Chen et al., 2011). Specifically, the families Lachnospiraceae (Chen et al., 2011) and Ruminococcaceae were decreased in patients with cirrhosis, whereas Enterobacteriaceae, Alcaligenaceae, and Fusobacteriaceae were significantly higher (Bajaj et al., 2012). In another study, a significant decrease in various *Lactobacilli* was demonstrated in human subjects with hepatitis B virus-related decompensated cirrhosis or liver transplant for hepatitis B cirrhosis (Wu et al., 2011). This might potentially explain why administration of *Lactobacillus* is beneficial in certain types of liver injury (Kapich et al., 2008; Vajro et al., 2011). Recently, Bacteroidaceae from the phylum Bacteroidetes have been found to be decreased in patients with chronic alcohol abuse compared to healthy controls (Mutlu et al., 2012). Compared to non-dysbiotic subjects, alcoholics with dysbiosis had smaller intestinal quantities of Bacteroidetes and higher levels of Proteobacteria. Contrary to the findings in experimental ALD in mice (Yan et al., 2011), the two aforementioned studies demonstrated a reduction of intestinal Bacteroidetes in patients with (at least partly) alcohol-induced cirrhosis (Chen et al., 2011; Mutlu et al., 2012). This difference might be due to a later stage of liver disease in patients and increased heterogeneity of patient population in these human studies as compared to well-controlled animal studies. In addition, different methods for sample collection, storage, DNA extraction, and sequencing might also explain these differences.

Many of the translational human microbiome studies are descriptive in nature. To advance the field and link changes in the microbiome to onset and progression of disease, further metagenomic, transcriptomic, and in particular metabolomic
studies are urgently needed. It is conceivable that not only translocation of PAMPs contributes to ALD, but changes in bacterial metabolites further modify liver disease.

**THE MICROBIOME AS TARGET IN ALCOHOLIC LIVER DISEASE**

An intricate interaction exists between bowel flora and liver in ALD. Alteration of normal bowel flora and significant overgrowth of harmful bacteria are described in animal models and humans with liver disease. These bacteria release endotoxins that increase damage to the integrity of gut flora and activate certain inflammatory pathways that lead to progression of alcohol liver disease (Forsyth et al., 2009). High endotoxin environment stimulates secretion of cytokines such as TNF-α, IL-1, and IL-6 that influence the development of liver fibrosis and cirrhosis (Gratz et al., 2010). Gut bacteria play a major role in the pathogenesis of ALD, and there are human trial studies that have shown that antibiotics and probiotics are effective in reducing the number of gram-negative bacteria and altering the gut flora to prevent further alcohol-induced liver injury and liver fibrosis. In addition, studies have demonstrated in human trials that use of probiotics can improve liver function by decreasing oxidative damage/stress, improving neutrophil function, and reducing endotoxin levels.

**Antibiotics**

Antibiotics have shown to provide beneficial effects in animal models with liver disease. Prophylactic use of antibiotics in patients with chronic liver disease is an established method of preventing infections in upper gastrointestinal hemorrhage and recurrent SBP (Leber et al., 2012). A randomized controlled trial showed that long-term prophylactic use of ciprofloxacin reduced the 1 year mortality rate in cirrhotic patients with low ascitic protein levels and without prior SBP episode (Terg et al., 2008). Similarly, a double blind, multi-center, placebo-controlled study investigating the long-term efficacy of norfloxacin in cirrhotic patients who had survived a previous episode of SBP found a significant reduction of the risk of SBP recurrence in the treated group at 1 year of follow-up (Gines et al., 1990).

Despite the established role of antibiotics in patients with hepatic encephalopathy, there are few human trials that have demonstrated the positive role of antibiotics in patients with ALD. According to one randomized controlled trial by Madrid et al., nine patients with alcoholic cirrhosis were treated with antibiotics that consisted of norfloxacin and neomycin during a period of 6 months. There was improvement of Child-Pugh status at 3 and 6 months treatment period (Madrid et al., 2001). Thus, long-term antibiotic treatment may improve the prognosis of ALD and result in a higher survival of cirrhotic patients. Despite improvement of liver function and reduction of infections in patients with ALD, it is also important to consider the negative effects of antibiotics on the gut mucosa. Prolonged use of antibiotics can sometimes increase the vulnerability of gut flora and lead to increased pathogenic bacterial colonization (Brandl et al., 2008). In addition, it is also important to consider that continued use of antibiotics can result in heightened bacterial resistance to these antibiotics and increased virulence of these pathogens (Novella et al., 1997; Campillo et al., 1998; Fernandez et al., 2002).

**Probiotics**

Probiotics are living non-pathogenic microorganisms that cause the growth of other microorganisms. They possess beneficial effects on the host by changing the gut microbiota profile, and this further leads to changes in the gut lumen that promotes anti-inflammatory effects. This improves gut barrier integrity and decreases the release of pro-inflammatory products by harmful bacteria (Forsyth et al., 2009; Gratza et al., 2010). By enhancing production of anti-inflammatory cytokines and secretion of antibacterial proteins, this further helps to reduce the production and translocation of bacterial endotoxin (Bongaerts et al., 2005; Forsyth et al., 2009; Gratza et al., 2010; Wang et al., 2011). Probiotics include lactic acid bacteria such as *Lactobacillus*, *Lactococcus*, and *Bifidobacteria*, or yeasts such as *Saccharomyces cerevisiae* (Bongaerts et al., 2005). Probiotics have been shown in several human clinical trials to prevent recurrent *Clostridium difficile* colitis and to maintain remission of pouchitis (Kirpich et al., 2008).

Probiotics including *Lactobacillus* and *Bifidobacterium* species have been used in human trials to study the beneficial effects of these microorganisms in patients with ALD. An investigation by Kirpich et al. consisted of a randomized, prospective study of 66 alcoholic male patients and 24 healthy, adult male controls concerning the therapeutic role of probiotics in treatment of ALD (Kirpich et al., 2008). In this study, alcoholic patients had reduced numbers of *Lactobacilli* and *Enterococci*, and increased number of *E. coli*. Of the alcoholic patients that received probiotics, the depressed numbers of *Bifidobacteria*, *Lactobacilli*, and *Enterococci* returned to the levels seen in healthy controls. Initial liver function tests, specifically AST, ALT, and GGT, were significantly elevated in the alcoholic group. After 5 days of probiotic therapy, patients treated with probiotics had significantly lower AST and ALT activity compared to the control group. In the subgroup of patients with well-defined alcoholic hepatitis, there was a significant reduction in ALT, AST, GGT, LDH, and total bilirubin values after probiotic therapy. The study further emphasizes that probiotic therapy is associated with greater improvement in liver enzymes.

Probiotic treatment can also help to restore neutrophil functions in patients with alcoholic cirrhosis. In an open-label study by Stadlbauer et al., 12 patients with alcoholic cirrhosis received *Lactobacillus casei Shirota* three times daily for 4 weeks (Stadlbauer et al., 2008). This was compared to 13 healthy controls and eight cirrhotic patients that did not receive probiotics. At baseline, the study showed that alcoholic cirrhotic patients have reduced neutrophil capacity. However, 28 days of treatment with *L. casei Shirota* revealed normalization of phagocytic activity in patients with alcoholic cirrhosis in the treatment group as opposed to the control group. The study also demonstrated that it is safe to administer the probiotics in this group of patients without adverse events. Another study by Loguericio et al. evaluated the effects of chronic therapy with probiotics on patients with alcoholic liver cirrhosis (Loguericio et al., 2005). In this study, 20 patients with alcoholic liver cirrhosis were treated with the
probic VSL#3, which is a mixture of 450 billion bacteria in various strains including *Streptococcus thermophilus*, *Bifidobacterium breve*, *B. longum*, *B. infantis*, *L. acidophilus*, *L. plantarum*, *L. casei*, and *L. bulgaricus* for 3 months. Patients treated with probiotic therapy presented with significantly reduced plasma levels of oxidative stress parameters, and there was improvement of liver function. An improvement of cytokine levels following treatment of VSL#3 was also noticed. A double-blind placebo-controlled study by Lata et al. investigated the effect of the probiotic *E. coli Nissle* on 34 patients with alcoholic cirrhosis (Lata et al., 2007). Overall, there was significant improvement of the intestinal colonization in the group treated with probiotics. In addition, an improvement of Child-Pugh Score in alcoholic cirrhotic patients treated with *E. coli Nissle* was observed. Probiotic treatment may improve the prognosis of ALD, but the effects of probiotics are strain-dependent. Therefore, further clinical studies are warranted to determine which probiotic strain should be used and which patient population should be treated.

**Prebiotics**

Prebiotics are complex carbohydrates that cannot be degraded by pancreatic and intestinal enzymes in the gastrointestinal tract (Yan et al., 2011). These carbohydrates are ultimately metabolized by gut microflora. Some examples of prebiotics include: lactulose, fructo-oligosaccharides (FOS), oats, and galacto-oligosaccharides (Gibson, 2008; Yan et al., 2011). There is a lack of current human trials that further elucidate the beneficial effect of prebiotics on patients with ALD. However, as mentioned above, there are animal studies that have shown that prebiotics help to slow liver damage progression. Prebiotics potentially possess beneficial effects in alcoholic liver disease by altering the gut microflora. However, additional clinical studies are needed to further clarify the possible benefits of the use of prebiotic therapy in patients with ALD.

**Synbiotics**

Synbiotics are mixtures of pre- and pro-biotics. Rats fed with synbiotics (*L. acidophilus*, *L. helveticus*, and *Bifidobacterium* in an enriched medium) displayed significantly diminished endotoxemia, BT, and liver damage in the course of acute pancreatitis and simultaneous heavy alcohol consumption (Marotta et al., 2005). A 7 day patient trial revealed a significant amelioration of Indocyanine Green clearance as measures of liver function in cirrhotic patients treated with synbiotics (*Pediococcus pentosaceus*, *Leuconostoc mesenteroides*, *L. paracasei subsp. paracasei*, and *L. plantarum* along with bioactive, fermentable fiber: betaglucan, inulin, pectin, and starch) as opposed to the placebo-controlled group in which no change was observed (Riordan et al., 2007). This synbiotic treatment may also result in an improvement of the Child-Pugh classification with a significant improvement in serum bilirubin, albumin concentrations, and international normalized ratio (INR). Furthermore, administration of the same synbiotics to cirrhotic patients with minimal hepatic encephalopathy (MHE) leads to significantly decreased ammonia levels and a reversal of MHE in 50% of the cases (Liu et al., 2004). It was also associated with significantly lower LPS levels in the blood, as was feeding of fermentable fiber alone. A meta-analysis demonstrated that synbiotics and both pre- and pro-biotics were associated with improvement of liver cirrhosis-associated MHE (Shukla et al., 2011). Amongst the prebiotics, lactulose seems to be the agent of choice for treatment of cirrhosis-associated MHE. Rishi et al. compared treatment with synbiotics (*L. acidophilus* and inulin) to *L. acidophilus* (probiotic) and inulin (prebiotic) alone, respectively, in *Salmonella typhimurium*-induced liver injury (Rishi et al., 2009). Mice fed with synbiotics were effectively protected against BT, lipid peroxidation, and liver damage, as were pre- and pro-biotic treated groups. Nevertheless, none of the observations suggested a synergistic effect in the synbiotic-supplemented group in this model. Thus, synbiotics—despite a wide range of composition—seem to alleviate liver damage and improve the prognosis in patients with cirrhosis.

**CONCLUSION**

ALD remains a leading cause of morbidity and mortality in the United States and worldwide. Since progression of ALD is partly driven by inflammatory responses to bacteria and their products, BT is a central event in the pathogenesis of ALD. This review highlights several mechanisms which facilitate BT, i.e., impaired bile flow, intestinal dysmotility, altered gastric pH, impaired intestinal immunity, and oxidative stress at the intestinal mucosa that increases intestinal permeability. Translocated bacterial PAMPs, in particular LPS, leads to TLR signaling and secretion of pro-inflammatory cytokines and chemokines, and this ultimately enhances alcoholic liver injury and steatohepatitis. Linked to BT and crucial in ALD are quantitative changes in the intestinal microflora. IBO is a driving force in the etiology of ALD. Given a leaky gut, overgrowth leads to increased luminal burden of bacterial products and toxins that can now traverse the gut barrier and encounter the liver as first organ in the body. This can be considered a second hit for hepatocytes that already encounter and metabolize ethanol. Recent advances in diagnostic technologies such as deep pyrosequencing have enabled a meticulous investigation of qualitative changes of the enteric microbiome. By means of these tools, dysbiosis has been described in preclinical and clinical ALD. Further studies are necessary to elucidate more clearly the exact impact of qualitative changes in the enteric flora on disease progression. Using metagenomics, transcriptomics, and metabolomics, future investigations need to focus on the identification of metabolites that mediate the effect of orally ingested alcohol to extraintestinal organs. Although there is promising but limited evidence that modulation of the microbiome using—biotics mitigate disease activity in patients, additional clinical studies on perhaps novel targets are still required before routine use of these agents is advisable.

**ACKNOWLEDGMENTS**

The study was supported in part by NIH grants K08 DK081830 and R01 AA020703 to Bernd Schnabl. This study was also supported by ABMRF/The Foundation for Alcohol Research to Bernd Schnabl.
poor performance of the glucose breath hydrogen test. J. Hepatol. 33, 382–386.

Bauer, T. M., Steinbruckner, B., Brinkmann, F. E., Ditzen, A. K., Schwach, H., Aponte, J. J., et al. (2001). Small intestinal bacterial overgrowth in patients with cirrho-
sic prevalence and relation with spontaneous bacterial peritonitis. Am. J. Gastroenterol. 96, 2962–2967.

Berg, R. D., and Garlington, A. W. (1979). Translocation of certain indigenous bacteria from the gas-
trointestinal tract to the mesenteric lymph nodes and other organs in a gnotobiotic mouse model. Infect. Immun. 23, 403–411.

Bjarnason, I., Peters, T. J., and Wise, R. J. (1984). The leaky gut of alcoholism: possible route of entry for toxic compounds. Lancet 1, 179–182.

Bode, C., and Bode, J. C. (2003). Effect of alcohol consumption on the gut. Best Pract. Res. Clin. Gastroenterol. 17, 575–592.

Bode, C., and Bode, J. C. (2005). Activation of the innate immune system and alcoholic liver disease: effects of ethanol per se or enhanced intestinal translocation of bacterial toxins induced by ethanol? Alcohol. Clin. Exp. Res. 29, 1665–1715.

Bode, C., Kugler, V., and Bode, J. C. (1987). Endotoxemia in patients with alcoholic and non-alcoholic cirrhosis and in subjects with no evidence of chronic liver disease following acute alcohol excess. J. Hepatol. 4, 8–14.

Bode, J. C., Bode, C., Heidelbach, R., Durr, H. K., and Martini, G. A. (1984). lejunal microflora in patients with chronic alcohol abuse. Hepatogastroenterology 31, 30–34.

Bongaerts, G., Severijnen, R., and Timmerman, H. (2005). Effect of antibiotics, probiotics and pre-
biotics in treatment for hepatic encephalopathy. Med. Hypotheses 64, 64–68.

Brandl, K., Pillatis, G., Mihu, C. N., Ubeda, C., Jia, T., Fleisher, M., et al. (2008). Vancomycin-resistant enter-
rocoeci exploit antibiotic-induced innate immune deficits. Nature 455, 804–807.

Camp, J. G., Kanther, M., Semova, L., and Raws, J. F. (2009). Patterns and scales in gastrointestinal micro-
bial ecology. Gastroenterology 136, 1986–2002.

Camprillo, B., Dupeyron, C., Richardet, J. P., Mangeney, N., and Leluau, G. (1998). Epidemiology of severe hospital-acquired infections in patients with liver cirrhosis: effect of long-term administration of norfloxacin. Clin. Infect. Dis. 26, 1066–1070.

Casasfont Morencos, F., De Las Heras Castano, G., Martin Ramos, L., Lopez Arias, M. I., Ledesma, E., and Pons Romero, F. (1996). Small bowel bacterial overgrowth in patients with alco-
holic cirrhosis. Dig. Dis. Sci. 41, 552–556.

Chang, C. S., Chen, G. H., Lien, H. C., and Yeh, H. Z. (1998). Small intest-
tine dysmotility and bacterial over-
growth in cirrhotic patients with spontaneous bacterial peritonitis. Hepatology 28, 1187–1190.

Chen, Y., Yang, F., Lu, H., Wang, B., Lei, D., Wang, Y., et al. (2011). Characterization of fecal microbial communities in patients with liver cirrhosis. Hepatology 54, 562–572.

Christou, L., Pappas, G., and Falagas, M. E. (2007). Bacterial infection-
related morbidity and mortality in cirrhosis. Am. J. Gastroenterol. 102, 1510–1517.

Clayburgh, D. R., Musch, M. W., Leitges, M., Fu, Y. X., and Turner, J. R. (2006). Coordinated epithelial NHE3 inhibition and barrier dysfunc-
tion are required for TNF-
mediated diarrhea in vivo. J. Clin. Invest. 116, 2682–2694.

Craig, R. M., and Atkinson, A. J. Jr. (1998). D-xylene testing: a review. Gastroenterology 95, 223–231.

Craig, R. M., and Ehrenpreis, E. D. (1999). D-xylene testing. J. Clin. Gastroenterol. 29, 143–150.

D’Amico, G., Garcia-Tsao, G., and Pagliaro, L. (2006). Natural his-
tory and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J. Hepatol. 44, 217–231.

Donald, I. P., Kitchingman, G., Donald, E., and Kupfer, R. M. (1992). The diagnosis of small bowel bacterial overgrowth in elderly patients. J. Am. Geriatr. Soc. 40, 692–696.

Eckburg, P. B., Bik, E. M., Bernstein, C. N., Purdom, E., Dethlefsen, L., Sargent, M., et al. (2005). Diversity of the human intestinal microbial flora. Science 308, 1635–1638.

Enomoto, N., Ikemizu, K., Yamashina, S., Hirose, M., Shimizu, H., Kitamura, T., et al. (2001). Kupfer cell sensitization by alcohol involves increased permeability to gut-derived endotoxin. Alcohol. Clin. Exp. Res. 25, 515–545.

Enomoto, N., Yamashina, S., Kono, H., Schemmer, P., Rivera, C. A., Enomoto, A., et al. (1999). Development of a new, simple rat model of early alcohol-induced liver injury based on sensitization of Kupffer cells. Hepatology 29, 1680–1689.

Fadl, A. A., Sha, J., Klimgel, G. R., Olano, J. P., Niesel, D. W., and Chopra, A. K. (2005). Murine lipoprotein is a critical outer membrane component involved in Salmonella enterica serovar typhimurium system infection. Infect. Immun. 73, 1081–1096.

Fernandez, J., Navasa, M., Gomez, J., Colmenero, J., Vila, J., Arroyo, V., et al. (2002). Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and nor-
floxacin prophylaxis. Hepatology 35, 140–148.

Ferrier, L., Berard, F., Debrauwer, L., Chabo, C., Langella, P., Bueno, L., et al. (2006). Impairment of the intestinal barrier by ethanol involves enteric microflora and mast cell activation in rodents. Am. J. Pathol. 168, 1148–1156.

Fleming, S., Toratani, S., Shead,
Donohue, T., Kashiwabara, Y., Vogel, S. N., and Metcalf, E. S. (2001). Pro- and anti-inflammatory gene expression in the murine small intestine and liver after chronic exposure to alcohol. Alcohol. Clin. Exp. Res. 25, 579–589.

Forsyth, C. B., Farhadi, A., Jakate, S. M., Tang, Y., Shaikh, M., and Keshavazarian, A. (2009). Lactobacillus GG treatment ame-
loriates alcohol-induced intestinal oxidative stress, gut leakiness, and liver injury in a rat model of alcoholic steatohepatitis. Alcohol 43, 163–172.

Fouts, D. E., Torralba, M., Nelson, K., Brenner, D. A., and Schnabl, B. (2012). Bacterial translocation and changes in the intestinal micro-
bicine in mouse models of liver dis-
 ease. J. Hepatol. 56, 1283–1292.

Frank, D. N., St Amand, A. L., Feldman, R. A., Boedecker, E. C., Harpaz, N., and Pace, N. R. (2007). Molecular-
phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc. Natl. Acad. Sci. U.S.A. 104, 13780–13785.

French, S. W. (2001). Intragastric ethanol infusion model for cellular and molecular studies of alcoholic liver disease. J. Biomed. Sci. 8, 20–27.

Fukui, H., Brauner, B., Bode, J. C., and Bode, C. (1991). Plasma endo-
toxin concentrations in patients with alcoholic and non-alcoholic liver disease: reevaluation with an improved chromogenic assay. J. Hepatol. 12, 162–169.

Gabele, E., Muhlbaier, M., Dorn, C., Weiss, T. S., Froh, M., Schnabl, B.,
et al. (2008). Role of TLR9 in hepatic stellate cells and experimental liver fibrosis. Biochem. Biophys. Res. Commun. 376, 271–276.

Guo, B., and Bataller, R. (2011). Alcoholic liver disease: pathogenesis and new therapeutic targets. Gastroenterology 141, 1572–1585.

Garcia-Tsao, G., Lee, F. Y., Barden, G. E., Cartun, R., and West, A. B. (1995). Bacterial translocation to mesenteric lymph nodes is increased in cirrhotic rats with ascites. Gastroenterology 108, 1835–1841.

Gibson, G. R. (2008). Probiotics as gut microbiota management tools. J. Clin. Gastroenterol. 42(Suppl. 2), S75–S79.

Gill, S. R., Pop, M., Deboy, R. T., Eckburg, P. B., Turnbaugh, P. J., Samuel, B. S., et al. (2006). Metagenomic analysis of the human distal gut microbiome. Science 312, 1355–1359.

Gines, P., Rimola, A., Planas, R., Guarner, C., Gonzalez-Navajas, J. M., Gratz, S. W., Mykkanen, H., and El-Gill, S. R., Pop, M., Deboy, R. T., Garcia-Tsao, G., Lee, F. Y., Barden, F., et al. (2008). The critical role of toll-like receptor (TLR) 4 in alcoholic liver disease is independent of the common TLR adapter MyD88. Hepatology 48, 1224–1231.

Huang, H., Shiffman, M. L., Friedman, S. N., Shidaka,ovna, N. A., Lebedeva, O. V., Sidorov, P. I., et al. (2008). Probiotics restore bowel flora and improve liver enzymes in human alcohol-induced liver injury: a pilot study. Alcohol 42, 675–682.

Koop, D. R., Klopfenstein, B., Limou, Y., and Thurman, R. G. (1997). Gadolinium chloride blocks alcohol-dependent liver toxicity in rats treated chronically with intra- gastric alcohol despite the induction of CYP2E1. Mol. Pharmacol. 51, 944–950.

Kudo, H., Takahara, T., Yata, K., Kawai, K., Zhang, W., and Sugiyama, T. (2009). Lipopolysaccharide triggered TNF-alpha-induced hepatic apoptosis in a murine non-alcoholic hepatosteatitis model. J. Hepatol. 51, 168–175.

Lata, J., Novotny, L., Pribramska, V., Jurankova, J., Fric, P., Kroupa, E., et al. (2007). A 7 gene signature identifies the risk of developing cirrhosis in patients with chronic hepatitis C. Hepatology 46, 297–306.

Inagaki, T., Fujita, K., Nozaki, Y., Shihara, Y., Suzuki, K., Mawatari, H., et al. (2011). Overexpression of CD14 in simple steatosis triggers the progression of nonalcoholic hepatosteatitis induced by increased sensitivity to low-dose lipopolysaccharide. Hepatology 54, 1166A.

Inokuchi, S., Tsukamoto, H., Park, E., Liu, Z. X., Bremner, D. A., and Seki, E. (2011). Toll-like receptor 4 mediates alcohol-induced steatohepatitis through bone marrow-derived and endogenous liver cells in mice. Alcohol. Clin. Exp. Res. 35, 1509–1518.

Isayama, F., Hines, I. N., Kremer, M., Milton, R. J., Byrd, C. L., Perry, A. W., et al. (2006). Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor. Proc. Natl. Acad. Sci. U.S.A. 103, 3920–3925.

Jakate, S., et al. (2001). Preventing fatigue and gut damage by oats supplementation ameliorates alcohol-induced liver damage in rats. J. Pharmacol. Exp. Ther. 299, 442–448.

Kerrin, P., and Wong, L. (1988). Breath hydrogen testing in bacterial overgrowth of the small intestine. Gastroenterology 95, 982–988.

Keshavarzian, A., Choudhary, S., Holmes, E. W., Yong, S., Banan, A., Jakate, S., et al. (2001). Preventing gut leakiness by oats supplementation alters alcohol-induced liver damage in rats. J. Pharmacol. Exp. Ther. 299, 442–448.

Kirpich, I. A., Solovieva, N. V., Leikhter, S. N., Shidakova, N. A., Lebedeva, O. V., Sidorov, P. I., et al. (2008). Probiotics restore bowel flora and improve liver enzymes in human alcohol-induced liver injury: a pilot study. Alcohol 42, 675–682.

Koop, D. R., Klopfenstein, B., Limou, Y., and Thurman, R. G. (1997). Gadolinium chloride blocks alcohol-dependent liver toxicity in rats treated chronically with intra-gastric alcohol despite the induction of CYP2E1. Mol. Pharmacol. 51, 944–950.

Kudo, H., Takahara, T., Yata, K., Kawai, K., Zhang, W., and Sugiyama, T. (2009). Lipopolysaccharide triggered TNF-alpha-induced hepatic apoptosis in a murine non-alcoholic hepatosteatitis model. J. Hepatol. 51, 168–175.

Leber, B., Spindelboeck, W., and Sheikh, M. Y. (2007). Beneficial effects of a probiotic VSL#3 on parameters of liver dysfunction in chronic liver disease. J. Clin. Gastroenterol. 39, 540–543.

Lorenzo-Zuniga, V., Bartoli, R., Planas, R., Hofmann, A. F., Vinado, B., and Nagy, L. R., et al. (2003). Oral bile acids reduce bacterial overgrowth, bacterial translocation, and endotoxemia in cirrhotic rats. Hepatology 37, 551–557.

Mandal, A. M., Cumsille, F., and Defilippi, C. (1997). Altered small bowel motility in patients with liver cirrhosis depends on severity of liver disease. Dig. Dis. Sci. 42, 738–742.

Mandal, A. M., Hurtado, C., Venegas, M., Cumsille, F., and Defilippi, C. (2001). Long-term treatment with cisapride and antibiotics in liver cirrhosis: effect on small intestinal motility, bacterial overgrowth, and liver function. Am. J. Gastroenterol. 96, 1251–1255.

Mandayam, S., Jamal, M. M., and Morgan, T.R. (2004). Epidemiology of alcoholic liver disease. Semin. Liver Dis. 24, 217–232.

Marotta, F., Barreto, R., Wu, C. C., Naito, Y., Gelosa, F., Lorenzetti, A., et al. (2005). Experimental acute alcohol pancreatitis-related liver damage and endotoxemia: synergistic but not monodirectional have a protective effect. Clin. J. Gastro. Dis. 6, 193–197.

Mathurin, P., Deng, Q. G., Keshavarzian, A., Choudhary, S., Holmes, E. W., and Tsukamoto, H. (2000). Exacerbation of alcoholic inflammation in rats with experimental small intestinal bacterial overgrowth. Gastroenterology 98, 410–415.
liver injury by enteral endotoxin in rats. *Hepatology* 32, 1008–1017.

McLoughlin, R. M., and Mills, K. H. (2011). Influence of gastrointestinal commensal bacteria on the immune responses that mediate allergy and asthma. *J. Allergy Clin. Immunol.* 127, 1097–1107. quiz: 1108–1099.

Metz, G., Gassull, M. A., Drasar, B. S., Jenkins, D. I., and Blendis, L. M. (1976). Breath-hydrogen test for small-intestinal bacterial colonisation. *Lancet* 1, 668–669.

Miele, L., Valenza, V., La Torre, G., Montalto, M., Cammarota, G., Ricci, R., et al. (2009). Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. *Hepatology* 49, 1877–1887.

Mutlu, E. A., Gillevent, P. M., Rangwala, H., Sikaroodi, M., Naqvi, A., Engen, P. A., et al. (2012). Colonic microbiota is altered in alcoholism. *Am. J. Physiol. Gastrointest. Liver Physiol.* 302, G966–G978.

Mutlu, E., Keshavarzian, A., Engen, P., Forsyth, C. B., Sikaroodi, M., and Gillevent, P. (2009). Intestinal dysbiosis: a possible mechanism of alcohol-induced endotoxemia and alcoholic steatohepatitis in rats. *Alcohol. Clin. Exp. Res.* 33, 1836–1846.

Nagaki, M., Sugiyama, A., Otsawa, Y., Naiki, T., Nakashima, S., Nozawa, Y., et al. (1999). Lethal hepatic apoptosis mediated by tumor necrosis factor receptor, unlike Fas-mediated apoptosis, requires hepatocyte sensitization in mice. *J. Hepatol.* 31, 997–1005.

Nanj, A. A., Khettry, U., and Sadrzadeh, S. M. (1994). Lactobacillus feeding reduces endotoxemia and severity of experimental alcoholic liver disease. *Proc. Soc. Exp. Biol. Med.* 205, 243–247.

Nanj, A. A., Khettry, U., and Sadrzadeh, S. M., and Yamanaka, T. (1993). Severity of liver injury in experimetal alcoholic liver disease. *Hepatology* 53, 649–660.

Nischakal, H. D., Berger, C., Aldenhoff, K., Thysen, L., Gentemann, M., Grunhage, F., et al. (2011). Toll-like receptor (TLR) 2 promoter and intron 2 polymorphisms are associated with increased risk for spontaneous bacterial peritonitis in liver cirrhosis. *J. Hepatol.* 55, 1010–1016.

Novella, M., Sola, R., Soriano, G., Andreu, M., Gana, J., Ortiz, J., et al. (1997). Continuous versus inpatient prophylaxis of the first episode of spontaneous bacterial peritonitis with teloraxocapin. *Hepatology* 25, 532–536.

O’Keefe, S. J. (2008). Nutrition and colonic health: the critical role of the microbiota. *Carr. Opin. Gastroenterol.* 24, 51–58.

Pande, C., Kumar, A., and Sarin, S. K. (2009). Small-intestinal bacterial overgrowth in cirrhosis is related to the severity of liver disease. *Aliment. Pharmacol. Ther.* 29, 1273–1281.

Papp, M., Norman, G. L., Vitlis, Z., Tornai, L., Aftorjai, I., Foldi, I., et al. (2010). Presence of anti-microbially antibodies in liver cirrhosis—a tell-tale sign of compromised immunity? PLoS ONE 5:e12957, doi: 10.1371/journal.pone.0012957.

Parks, R. W., Clements, W. D., Pope, C., Halliday, M. I., Rowlands, B. L., and Diamond, T. (1996). Bacterial translocation and gut microflora in obstructive jaundice. *J. Anat.* 189(Pt 3), 561–565.

Parlesak, A., Schafer, C., Schutz, T., Bode, J. C., and Bode, C. (2000). Increased intestinal permeability to macromolecules and endotoxin in patients with chronic alcohol abuse in different stages of alcohol-induced liver disease. *J. Hepatol.* 32, 742–747.

Paula, H., Asrani, S. K., Boetticher, N. C., Pedersen, R., Shah, V. H., and Diamond, T. (1996). Bacterial overgrowth and intestinal motility in patients with chronic alcohol abuse and alcoholic liver injury. *J. Liver. Inflamm.* 20, 51–60.

Petrasek, J., Holakova, J., Hamersky, V., and Kluwe, J., and Kirschning, C. J. (1999). Toll-like receptor 2 promoter and intron 2 polymorphisms are associated with increased risk for spontaneous bacterial peritonitis in liver cirrhosis. *J. Gastroenterol. Hepatol.* 24, 51–58.

Rao, R. K. (1998). Acetaldehyde-induced increase in paracellular permeability in Caco-2 cell monolayer. *Alcohol. Clin. Exp. Res.* 22, 1724–1730.

Rao, R. K., Seth, A., and Sheth, P. (2004). Recent advances in alcoholic liver disease, I. Role of intestinal permeability and endotoxia in alcoholic liver disease. *Am. J. Gastroenterol.* *Liver Physiol.* 286, G881–G884.

Riordan, S. M., Skinner, N. A., McVler, C. J., Liu, Q., Bengmark, S., Bihari, D., et al. (2007). Synthetic-associated improvement in liver function in cirrhotic patients: relation to changes in circulating cytokine messenger RNA and protein levels. *Microb. Ecol. Health Dis.* 19, 7–16.

Rishi, P., Mavi, S. K., Bharrhan, S., Shukla, G., and Tewari, R. (2009). Protective efficacy of probiotic alone or in conjunction with a probiotic in Salmonella-induced liver damage. *FEMS Microb. Ecol.* 69, 222–230.

Runyon, B. A., Squier, S., and Borzio, M. (1994). Translocation of gut bacteria into the bloodstream in cirrhosis. *Scand. J. Gastroenterol.* 32, 556–563.

Riordan, S. M., Skinner, N. A., McVler, C. J., Liu, Q., Bengmark, S., Bihari, D., et al. (2007). Synthetic-associated improvement in liver function in cirrhotic patients: relation to changes in circulating cytokine messenger RNA and protein levels. *Microb. Ecol. Health Dis.* 19, 7–16.

Rishi, P., Mavi, S. K., Bharrhan, S., Shukla, G., and Tewari, R. (2009). Protective efficacy of probiotic alone or in conjunction with a probiotic in Salmonella-induced liver damage. *FEMS Microb. Ecol.* 69, 222–230.

Sanchez, E., Casafont, F., Guerra, A., De Benito, I., and Pons-Romero, F. (2005). Role of intestinal bacterial overgrowth and intestinal motility in bacterial translocation in experimental cirrhosis. *Rev. Esp. Enferm. Dig.* 97, 805–814.

Sato, M., Ando, S., Shinoda, T., and Yamazaki, M. (2008). Clearance of bacterial lipopolysaccharides and lipid A by the liver and the role of argininosuccinate synthase. *Innate Immun.* 14, 51–60.

Savage, D. C. (1987). Microbial ecology of the gastrointestinal tract. *Annu. Rev. Microbiol.* 31, 107–133.

Schafer, C., Parlesak, A., Schutt, C., Bode, J. C., and Bode, C. (2002). Concentrations of lipopolysaccharide-binding protein, bacterial/ permeability-increasing protein, soluble CD14 and plasma lipids in patients with alcoholic cirrhosis of the liver. *Digestion* 66, 80–88.

Shindo, K., Machida, M., Miyakawa, K., and Fukumura, M. (1993). A syndrome of cirrhosis, achlorhydria, small intestinal bacterial overgrowth, and fat malabsorption. *Am. J. Gastroenterol.* 88, 2084–2091.

Sorensen, T. I., Orholm, M., Bentsen, K. D., Høybye, G., Eghøje, K., and Christoffersen, P. (1984). Prospective evaluation of alcohol abuse and alcoholic liver injury in men as predictors of development of cirrhosis. *Lancet* 2, 241–244.

Stadlbauer, V., Mookerjee, R. P., Hodges, S., Wright, G. A., Davies, N. A., and Jalan, R. (2008). Effect of probiotic treatment on deranged neutrophil function and cytokine responses in patients with compensated alcoholic cirrhosis. *J. Hepatol.* 48, 945–951.

Such, J., Guardiola, J. V., De Juan, J., Casellas, J. A., Pascual, S., Aparicio, J. R., et al. (2002). Ultrastructural characteristics of distal duodenal mucosa in patients with cirrhosis. *Eur. J. Gastroenterol.* 14, 371–376.

Tabata, T., Tani, T., Endo, Y., and Hanasawa, K. (2002). Bacterial translocation and peptidoglycan

Hartmann et al. Microbiome and gut leakiness in ALD

October 2012 | Volume 3 | Article 402 | 9

www.frontiersin.org
Toll-like receptor 4 is involved in the mechanism of early alcohol-induced liver injury in mice. Hepatology 34, 101–108.

Vajro, P., Mandato, C., Licenziati, M. R., Franzese, A., Vitale, D. F., Lenta, S., et al. (2011). Effects of Lactobacillus rhamnosus strain GG in pediatric obesity-related liver disease. J. Pediatr. Gastroenterol. Nutr. 52, 740–743.

Wang, F., Graham, W. V., Wang, Y., Witkowski, E. D., Schwarz, B. T., and Turner, J. R. (2005). Interferon-gamma and tumor necrosis factor-alpha synergize to induce intestinal epithelial barrier dysfunction by up-regulating myosin light chain kinase expression. Am. J. Pathol. 166, 409–419.

Wang, Y., Kirpich, I., Liu, Y., Ma, Z., Barve, S., McClain, C. J., et al. (2011). Lactobacillus rhamnosus GG treatment potentiates intestinal hypoxia-inducible factor, promotes intestinal integrity and ameliorates alcohol-induced liver injury. Am. J. Pathol. 179, 2866–2875.

Wigg, A. J., Roberts-Thomson, I. C., Dymock, R. B., McCarthy, P. J., Grose, R. H., and Cummins, A. G. (2001). The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis. Gut 48, 206–211.

Wu, Z. W., Lu, H. F., Wu, J., Zuo, J., Chen, P., Sheng, J. F., et al. (2011). Assessment of the fecal lactobacilli population in patients with hepatitis B virus-related decompensated cirrhosis and hepatitis B cirrhosis treated with liver transplant. Microb. Ecol. 63, 929–937.

Yan, A. W., Fouts, D. E., Brandl, J., Starckel, P., Torralba, M., Schott, E., et al. (2011). Enteric dysbiosis associated with a mouse model of alcoholic liver disease. Hepatology 53, 96–105.

Ye, D., Li, F. Y., Lam, K. S., Li, H., Jia, W., Wang, Y., et al. (2012). Toll-like receptor-4 mediates obesity-induced non-alcoholic steatohepatitis through activation of X-box binding protein-1 in mice. Gut 61, 1058–1067.

Yin, M., Bradford, B. U., Wheeler, M. D., Uesugi, T., Froh, M., Goyert, S. M., et al. (2001). Reduced early alcohol-induced liver injury in CD14-deficient mice. J. Immunol. 166, 4737–4742.

Yoon, Y. H., and Yi, H. Y. (2010). Surveillance Report #88, Liver Cirrhosis Mortality in the United States, 1970–2007. Bethesda, MD: National Institute on Alcohol Abuse and Alcoholism.

Yoshimura, A., Lien, E., Ingalls, R. R., Tuomanen, E., Dziarski, R., and Golenbock, D. (1999). Cutting edge: recognition of Gram-positive bacterial cell wall components by the innate immune system occurs via Toll-like receptor 2. J. Immunol. 163, 1–5.

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Received: 24 June 2012; accepted: 24 September 2012; published online: 11 October 2012.

Citation: Hartmann P, Chen W-C and Schnabl B (2012) The intestinal microbiome and the leaky gut as therapeutic targets in alcoholic liver disease. Front. Physio. 3:402. doi: 10.3389/fphys.2012.00402

This article was submitted to Frontiers in Gastrointestinal Sciences, a specialty of Frontiers in Physiology.

Copyright © 2012 Hartmann, Chen and Schnabl. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in other forums, provided the original authors and source are credited and subject to any copyright notices concerning any third-party graphics etc.